We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
IFINWIL (Norgine Pty Ltd)
Product name
IFINWIL
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
167 (255 working days)
Active ingredients
eflornithine hydrochloride
Registration type
EOI
Indication
Ifinwil is indicated for the treatment of adults and paediatric patients with high-risk neuroblastoma (HRNB) who have responded to prior multiagent, multimodality therapy.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.